
### [NCIT:C138195](http://purl.obolibrary.org/obo/NCIT_C138195)
**Label:** High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

**Subclasses:** [NCIT:C131913](http://purl.obolibrary.org/obo/NCIT_C131913) (High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements), [NCIT:C125904](http://purl.obolibrary.org/obo/NCIT_C125904) (High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements), 

**Class expressions from DL-Learner:**

- [NCIT:C132018](http://purl.obolibrary.org/obo/NCIT_C132018) (MYC Gene Rearrangement) 62.50%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C36449](http://purl.obolibrary.org/obo/NCIT_C36449) (Clonal BCL6 Gene Rearrangement))) 62.50%
- [NCIT:C133155](http://purl.obolibrary.org/obo/NCIT_C133155) (Gene Rearrangement Abnormality) 54.48%
- Thing 52.03%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39079](http://purl.obolibrary.org/obo/NCIT_C39079) (Fc Epsilon Receptor I Signaling Pathway BioCarta))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39072](http://purl.obolibrary.org/obo/NCIT_C39072) (Erk1/Erk2 MAPK Signaling Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39071](http://purl.obolibrary.org/obo/NCIT_C39071) (Neuronal Survival Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39069](http://purl.obolibrary.org/obo/NCIT_C39069) (ErbB3 Receptor Recycling Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39067](http://purl.obolibrary.org/obo/NCIT_C39067) (EPO Signaling Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39066](http://purl.obolibrary.org/obo/NCIT_C39066) (Erythropoietin Neuroprotection Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39059](http://purl.obolibrary.org/obo/NCIT_C39059) (Map Kinase Inactivation of SMRT Corepressor Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39058](http://purl.obolibrary.org/obo/NCIT_C39058) (EGF Signaling Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39056](http://purl.obolibrary.org/obo/NCIT_C39056) (Vesicle Transport Pathway))) 47.86%
- [NCIT:C132020](http://purl.obolibrary.org/obo/NCIT_C132020) (BCL6 Gene Rearrangement) and (not ([NCIT:C39055](http://purl.obolibrary.org/obo/NCIT_C39055) (Phospholipid Signaling Pathway))) 47.86%


